An evidence-based #fatigue management #digitalhealth solution for persons with #MultipleSclerosis. @BusinessFinland project by @MIPT_Oulu & @m3sOulu at @UniOulu
In a small study, the gamified mobile app helped adults with MS manage daily fatigue by becoming more aware of their changing energy levels. https://t.co/YEwSdi8KSh #news
.@buscandoagodot from @UniOulu is one of the winners of the MCAA Best Innovator Award 2023.
He specialises in digital health solutions for people with chronic conditions.
“The award is a big shout-out for all the hard work we've been doing.” 🏆
https://t.co/MjB3WkA2oY
My @TEDxOuluFI talk about diversity in IT is now live on YouTube! The talk is about my own story as IT professional, and discusses the importance of diversity for innovation. Watch and join the conversation: https://t.co/juJ1ozjj0h #TEDx#Diversity#WomenInSTEM#inclusion
El médico y científico 🇦🇷 Dr. Guido Giunti, ha sido nominado como finalista para el Global Patient Innovator Award del @HIMSS
Fecha límite para la votación pública es el 28/11. Acompañemos a Guido con el voto! 👇
https://t.co/4Hmigyyhcg
@IICN_ie@tcddublin#argentinosenirlanda
M3S docent Guido Giunti @buscandoagodot is one of the finalists for HIMSS Global Patient Innovator Award for his work in @morestaminaapp with MS patients funded by @BusinessFinland. Help Guido to win and vote 🤩
A reminder that tomorrow is our virtual National Conference. We have some interesting topics planned with excellent speakers. There still time to sign up https://t.co/YQthNmkTLS
#OrgulloUBA
Guido Giunti es un médico graduado en @UBAonline que reside en Finlandia y trabaja en el desarrollo de @morestaminaapp, una aplicación para ayudar a a las personas con esclerosis múltiple en su vida diaria.
https://t.co/FqMpNQZvEO
@morestaminaapp and @buscandoagodot in CNN radio interview about digital health, the design process and the future of new health technologies https://t.co/mGyS415AAQ. @UniOulu@MIPT_Oulu
Available data shows that vaccinations don't exacerbate #MS, provoke relapse or prevent DMTs to be effective. It isn't recommended to discontinue or modify DMT treatment due to the risk of disease reactivation. All people with MS should be vaccinated #EMSPVirtual2021
@SilverGorilla2 Hi Anne! At the moment we are only testing with our clinical partners in Finland, Spain, Argentina and Switzerland. If you are interested, get in touch with your healthcare professional or institution so that we can see how to start studies where you are :)
We were featured today in #Finnish newspaper @Kaleva_fi. In the article, @buscandoagodot talked a bit about the direction of the project and goals
https://t.co/yRUNtywWph